A measure that was under consideration in the Republican-sponsored tax bill in the Senate that would have impacted how pharmacy benefit managers work with Medicare is likely to be dropped.
The policy would have prevented PBMs, also known as “drug middlemen,” from having their compensation linked to the list prices of medications.
The development, reported by Bloomberg, is seen as a positive for Cigna (NYSE:CI), CVS Health (NYSE:CVS), and UnitedHealth Group (NYSE:UNH), which operate the largest PBMs.
Dear Readers: We recognize that politics often intersect with the financial news of the day, so we invite you to click here to join the separate political discussion.
